Auryxia is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Akebia Therapeutics, Inc.. The primary component is Tetraferric Tricitrate Decahydrate.
| Product ID | 59922-631_122f6283-fd52-424c-b174-e7a3bde61742 |
| NDC | 59922-631 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Auryxia |
| Generic Name | Ferric Citrate |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2014-09-17 |
| Marketing Category | NDA / NDA |
| Application Number | NDA205874 |
| Labeler Name | Akebia Therapeutics, Inc. |
| Substance Name | TETRAFERRIC TRICITRATE DECAHYDRATE |
| Active Ingredient Strength | 210 mg/1 |
| Pharm Classes | Iron [CS], Parenteral Iron Replacement [EPC], Phosphate Binder [EPC], Phosphate Chelating Activity [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2014-09-17 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA205874 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2014-09-17 |
| Marketing Category | NDA |
| Application Number | NDA205874 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2014-09-17 |
| Marketing End Date | 2019-12-20 |
| Marketing Category | NDA |
| Application Number | NDA205874 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2014-09-17 |
| Marketing End Date | 2019-12-20 |
| Ingredient | Strength |
|---|---|
| TETRAFERRIC TRICITRATE DECAHYDRATE | 210 mg/1 |
| SPL SET ID: | aadd18e0-3752-11e4-8510-0800200c9a66 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() AURYXIA 86390566 4956680 Live/Registered |
Keryx Biopharmaceuticals, Inc. 2014-09-10 |